Could a shock drug help ARDS patients breathe easier?
NCT ID NCT05241067
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called centhaquine in 80 adults with moderate to severe ARDS, a life-threatening lung condition. The drug is added to standard care to see if it improves oxygen levels and reduces deaths. Participants must be in the ICU and start treatment within 48 hours of diagnosis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immune clues may unlock better ECMO care for lung failure patients
- New study aims to Fine-Tune ventilator strategies for ARDS patients
- Can the right dose and timing of steroids save more lives in ARDS?
- New inflatable cushion could revolutionize ICU patient repositioning
- Tailored breathing support may reduce lung injury in ECMO patients
- ARDS ventilator tool faces reliability test